Xi'an No.3 Hospital
Xi'an, Shaanxi, 710018, China
Location status: Recruiting
NCT Number: NCT03607565
This observational study focus on a new parameter of cerebral perfusion derived form digital substraction angiography.
Interested in participating?
Request InfoAll sexes
Observational
Xi'an, Shaanxi, 710018, China
Location status: Recruiting
Ischemic cerebrovascular disease is an important cause of death and disability in the world. Digital Subtraction Angiography (DSA) is the golden index for evaluating cerebral blood vessels. We introduced a new parameter derived from DSA to evaluate the perfusion to predict the outcomes in acute stroke with large vessel occlusion.
To study the possible relationship between the new parameter of cerebral perfusion derived from DSA and outcomes in cerebral ischemia(modified Rankin Scale), we intend to retrospectively analyze the images derived from patients who undergone the DSA and follow-up outcomes(modified Rankin Scale).
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
1.cerebral hemorrhage
Time frame: 3 months to 2 years
Results are reported as odds ratios (ORs) with 95% confidence intervals (CIs).
Time frame: 3 months to 2 years
Results are reported as odds ratios (ORs) with 95% confidence intervals (CIs).
Contact information is provided by the study sponsor or research team.
Xi'an No.3 Hospital
Other Gov
The Association Between a New Parameter Derived From DSA and Outcomes in Cerebral Ischemia
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT02795052
ALS, Alzheimer Disease
Westport, Connecticut, United States
View Trial DetailsNCT07324421
Brain Diseases, Brain Injuries, Vascular
Montpellier, Herault, France
View Trial DetailsNCT03318432
Acute Stroke, Brain Diseases
San Francisco, California, United States
View Trial DetailsNCT04998357
Brain Diseases, Brain Ischemia
Seattle, Washington, United States
View Trial Details